GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item5.03. Amendments to Certificate of Incorporation or Bylaws;
Change in Fiscal Year.

On February13, 2017, the Company filed with the Secretary of
State of the State of Nevada Certificate of Designation of
Preferences, Rights and Limitations of Common Stock (Class W),
establishing the terms of the Common Stock (Class W). A copy of
the Certificate of Designation of Preferences, Rights and
Limitations of Common Stock (Class W) is included as an exhibit
to this report and is incorporated by reference into this Item
5.03.

Item9.01 Financial Statements and Exhibits

(d) Exhibits

About GALECTIN THERAPEUTICS INC. (NASDAQ:GALT)

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Recent Trading Information

GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) closed its last trading session 00.00 at 1.47 with 221,036 shares trading hands.